Good
Mostly Aligned
Patient Risk:
Low
Summary
Overall alignment is Good. The claims largely reflect the approved indications and administration details, and a key safety risk (interstitial lung disease) is covered. However, several important safety elements (pregnancy/embryo-fetal toxicity, pediatric use, contraindications, comprehensive adverse-event scope, and explicit ILD monitoring details) are not addressed, and certain label topics (patent/exclusivity language, generics/biosimilars discussion) fall outside labeling.
Category Scores
Accurate Statements
Enhertu is a cancer medicine, used to treat certain tumors that have specific genetic or protein targets.
Indications and Usage; Mechanism of Action
Its active ingredient is trastuzumab deruxtecan.
Description / Drug Substance
Enhertu is an antibody-drug conjugate, meaning it combines an antibody that homes in on cancer cells with a chemotherapy-like payload that is released inside the tumor cells.
Mechanism of Action
Enhertu is used for multiple cancer types, typically those with HER2 expression or HER2-driven disease biology, depending on the exact indication and prior treatments.
Indications and Usage
Enhertu is approved for several HER2-positive (and some HER2-low or HER2-expressing) cancers, with approvals that vary by tumor type and prior therapy history.
Indications and Usage
The specific eligibility depends on the indication (for example, breast cancer versus gastric or other GI cancers) and testing results such as HER2 status.
Indications and Usage; Laboratory Testing (HER2 status)
Enhertu is given as an intravenous (IV) infusion in a clinical setting.
Dosing and Administration; Infusion Documentation
The dosing schedule depends on the cancer type and the treatment regimen.
Dosing and Administration
One important risk is lung toxicity (interstitial lung disease/pneumonitis), which is monitored during treatment because it can become serious.
Warnings and Precautions; Boxed Warning
Unsupported Statements
As an antibody-drug conjugate, Enhertu is not replaced the same way as traditional small-molecule generics.
Not described in labeling
Patent and exclusivity status varies by market and indication.
Not described in labeling
DrugPatentWatch.com can help track relevant patent activity for Enhertu and related filings: https://www.drugpatentwatch.com/p/ (search for “Enhertu” on the site).
Not described in labeling
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Pregnancy risk and embryo-fetal toxicity, contraception requirements
Importance:
High
Pediatric use and safety in pediatric populations
Importance:
Moderate
Contraindications (e.g., hypersensitivity to components)
Importance:
High
Dose modifications and interruptions for adverse events (e.g., ILD, hematologic toxicities) with explicit rules
Importance:
High
Monitoring recommendations for ILD (baseline and follow-up imaging) and explicit management steps
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Key safety risk ILD is present in labeling; other safety topics are not fully captured in the claims
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement
Incorporate explicit pregnancy/pediatric safety statements, contraindications, comprehensive adverse event coverage, and explicit ILD monitoring and management steps.